{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T18:44:12Z","timestamp":1795113852694,"version":"4.10.3"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["CA141975,"],"award-info":[{"award-number":["CA141975,"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RR150072"],"award-info":[{"award-number":["RR150072"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lack of proper innate sensing inside tumor microenvironment (TME) limits T cell-targeted immunotherapy. NAD(P)H:quinone oxidoreductase 1 (NQO1) is highly enriched in multiple tumor types and has emerged as a promising target for direct tumor-killing. Here, we demonstrate that NQO1-targeting prodrug \u03b2-lapachone triggers tumor-selective innate sensing leading to T cell-dependent tumor control. \u03b2-Lapachone is catalyzed and bioactivated by NQO1 to generate ROS in NQO1\n                    <jats:sup>high<\/jats:sup>\n                    tumor cells triggering oxidative stress and release of the damage signals for innate sensing. \u03b2-Lapachone-induced high mobility group box 1 (HMGB1) release activates the host TLR4\/MyD88\/type I interferon pathway and Batf3 dendritic cell-dependent cross-priming to bridge innate and adaptive immune responses against the tumor. Furthermore, targeting NQO1 is very potent to trigger innate sensing for T cell re-activation to overcome checkpoint blockade resistance in well-established tumors. Our study reveals that targeting NQO1 potently triggers innate sensing within TME that synergizes with immunotherapy to overcome adaptive resistance.\n                  <\/jats:p>","DOI":"10.1038\/s41467-019-11238-1","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T06:04:13Z","timestamp":1563516253000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":91,"title":["NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance"],"prefix":"10.1038","volume":"10","author":[{"given":"Xiaoguang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3980-8440","authenticated-orcid":false,"given":"Zhida","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanhui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Boothman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiumei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4809-825X","authenticated-orcid":false,"given":"Yang-Xin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"11238_CR1","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian, S. L., Drake, C. G. & Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450\u2013461 (2015).","journal-title":"Cancer Cell"},{"key":"11238_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","volume":"36","author":"KE Pauken","year":"2015","unstructured":"Pauken, K. E. & Wherry, E. J. Overcoming T cell exhaustion in infection and cancer. Trends Immunol. 36, 265\u2013276 (2015).","journal-title":"Trends Immunol."},{"key":"11238_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"11238_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/bjc.2017.434","volume":"118","author":"RW Jenkins","year":"2018","unstructured":"Jenkins, R. W., Barbie, D. A. & Flaherty, K. T. Mechanisms of resistance to immune checkpoint inhibitors. Br. J. Cancer 118, 9\u201316 (2018).","journal-title":"Br. J. Cancer"},{"key":"11238_CR5","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1126\/science.360.6389.588","volume":"360","author":"K Garber","year":"2018","unstructured":"Garber, K. A new cancer immunotherapy suffers a setback. Science 360, 588 (2018).","journal-title":"Science"},{"key":"11238_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","volume":"114","author":"Y Lee","year":"2009","unstructured":"Lee, Y. et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood 114, 589\u2013595 (2009).","journal-title":"Blood"},{"key":"11238_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1146\/annurev-immunol-032414-112043","volume":"33","author":"SR Woo","year":"2015","unstructured":"Woo, S. R., Corrales, L. & Gajewski, T. F. Innate immune recognition of cancer. Annu. Rev. Immunol. 33, 445\u2013474 (2015).","journal-title":"Annu. Rev. Immunol."},{"key":"11238_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","volume":"140","author":"O Takeuchi","year":"2010","unstructured":"Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. Cell 140, 805\u2013820 (2010).","journal-title":"Cell"},{"key":"11238_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.immuni.2018.03.007","volume":"48","author":"SA Patel","year":"2018","unstructured":"Patel, S. A. & Minn, A. J. Combination cancer therapy with immune checkpoint blockade: mechanisms and strategies. Immunity 48, 417\u2013433 (2018).","journal-title":"Immunity"},{"key":"11238_CR10","doi-asserted-by":"publisher","first-page":"5931","DOI":"10.1038\/onc.2016.104","volume":"35","author":"C Hernandez","year":"2016","unstructured":"Hernandez, C., Huebener, P. & Schwabe, R. F. Damage-associated molecular patterns in cancer: a double-edged sword. Oncogene 35, 5931\u20135941 (2016).","journal-title":"Oncogene"},{"key":"11238_CR11","first-page":"883","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov, S. I., Greten, F. R. & Karin, M. Immunity. Inflamm. Cancer Cell 140, 883\u2013899 (2010).","journal-title":"Inflamm. Cancer Cell"},{"key":"11238_CR12","doi-asserted-by":"publisher","first-page":"e1386829","DOI":"10.1080\/2162402X.2017.1386829","volume":"6","author":"AD Garg","year":"2017","unstructured":"Garg, A. D. et al. Trial watch: immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 6, e1386829 (2017).","journal-title":"Oncoimmunology"},{"key":"11238_CR13","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu, A. et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20, 1301\u20131309 (2014).","journal-title":"Nat. Med."},{"key":"11238_CR14","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","volume":"28","author":"L Galluzzi","year":"2015","unstructured":"Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L. & Kroemer, G. Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer cell 28, 690\u2013714 (2015).","journal-title":"Cancer cell"},{"key":"11238_CR15","doi-asserted-by":"publisher","first-page":"8846","DOI":"10.1073\/pnas.92.19.8846","volume":"92","author":"R Li","year":"1995","unstructured":"Li, R., Bianchet, M. A., Talalay, P. & Amzel, L. M. The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. Proc. Natl Acad. Sci. USA 92, 8846\u20138850 (1995).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"11238_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13593","volume":"7","author":"ET Oh","year":"2016","unstructured":"Oh, E. T. et al. NQO1 inhibits proteasome-mediated degradation of HIF-1alpha. Nat. Commun. 7, 13593 (2016).","journal-title":"Nat. Commun."},{"key":"11238_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1227-8","volume":"15","author":"Z Li","year":"2015","unstructured":"Li, Z. et al. NQO1 protein expression predicts poor prognosis of non-small cell lung cancers. BMC Cancer 15, 207 (2015).","journal-title":"BMC Cancer"},{"key":"11238_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-414","volume":"14","author":"Y Ma","year":"2014","unstructured":"Ma, Y. et al. NQO1 overexpression is associated with poor prognosis in squamous cell carcinoma of the uterine cervix. BMC Cancer 14, 414 (2014).","journal-title":"BMC Cancer"},{"key":"11238_CR19","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.ccell.2016.11.006","volume":"30","author":"X Huang","year":"2016","unstructured":"Huang, X. et al. Leveraging an NQO1 bioactivatable drug for tumor-selective use of poly(ADP-ribose) polymerase inhibitors. Cancer Cell 30, 940\u2013952 (2016).","journal-title":"Cancer Cell"},{"key":"11238_CR20","doi-asserted-by":"publisher","first-page":"5416","DOI":"10.1074\/jbc.275.8.5416","volume":"275","author":"JJ Pink","year":"2000","unstructured":"Pink, J. J. et al. NAD(P)H:quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. J. Biol. Chem. 275, 5416\u20135424 (2000).","journal-title":"J. Biol. Chem."},{"key":"11238_CR21","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.redox.2016.10.010","volume":"10","author":"CM Doskey","year":"2016","unstructured":"Doskey, C. M. et al. Tumor cells have decreased ability to metabolize H2O2: implications for pharmacological ascorbate in cancer therapy. Redox Biol. 10, 274\u2013284 (2016).","journal-title":"Redox Biol."},{"key":"11238_CR22","doi-asserted-by":"publisher","first-page":"3038","DOI":"10.1158\/0008-5472.CAN-11-3135","volume":"72","author":"X Huang","year":"2012","unstructured":"Huang, X. et al. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis. Cancer Res. 72, 3038\u20133047 (2012).","journal-title":"Cancer Res."},{"key":"11238_CR23","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1158\/1535-7163.MCT-15-0765","volume":"15","author":"LS Li","year":"2016","unstructured":"Li, L. S. et al. NQO1-mediated tumor-selective lethality and radiosensitization for head and neck cancer. Mol. Cancer Ther. 15, 1757\u20131767 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"11238_CR24","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ccell.2016.02.004","volume":"29","author":"H Tang","year":"2016","unstructured":"Tang, H. et al. Facilitating T cell infiltration in tumor microenvironment overcomes resistance to PD-L1 blockade. Cancer Cell 29, 285\u2013296 (2016).","journal-title":"Cancer Cell"},{"key":"11238_CR25","doi-asserted-by":"publisher","first-page":"6153","DOI":"10.1158\/0008-5472.CAN-16-1260","volume":"76","author":"JJ Morton","year":"2016","unstructured":"Morton, J. J., Bird, G., Refaeli, Y. & Jimeno, A. Humanized mouse xenograft models: narrowing the tumor-microenvironment gap. Cancer Res. 76, 6153\u20136158 (2016).","journal-title":"Cancer Res."},{"key":"11238_CR26","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1172\/JCI96061","volume":"128","author":"H Tang","year":"2018","unstructured":"Tang, H. et al. PD-L1 on host cells is essential for PD-L1 blockade-mediated tumor regression. J. Clin. Invest. 128, 580\u2013588 (2018).","journal-title":"J. Clin. Invest."},{"key":"11238_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1158\/2159-8290.CD-15-0510","volume":"6","author":"AR Sanchez-Paulete","year":"2016","unstructured":"Sanchez-Paulete, A. R. et al. Cancer immunotherapy with immunomodulatory Anti-CD137 and Anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov. 6, 71\u201379 (2016).","journal-title":"Cancer Discov."},{"key":"11238_CR28","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1016\/j.ccell.2014.11.010","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz, M. L. et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26, 938 (2014).","journal-title":"Cancer Cell"},{"key":"11238_CR29","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon, H. et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44, 924\u2013938 (2016).","journal-title":"Immunity"},{"key":"11238_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/cr.2016.149","volume":"27","author":"L Corrales","year":"2017","unstructured":"Corrales, L., Matson, V., Flood, B., Spranger, S. & Gajewski, T. F. Innate immune signaling and regulation in cancer immunotherapy. Cell Res. 27, 96\u2013108 (2017).","journal-title":"Cell Res."},{"key":"11238_CR31","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.immuni.2014.10.019","volume":"41","author":"L Deng","year":"2014","unstructured":"Deng, L. et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type i interferon-dependent antitumor immunity in immunogenic tumors. Immunity 41, 843\u2013852 (2014).","journal-title":"Immunity"},{"key":"11238_CR32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/nri3845","volume":"15","author":"L Zitvogel","year":"2015","unstructured":"Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J. & Kroemer, G. Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405\u2013414 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"11238_CR33","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1038\/nm1622","volume":"13","author":"L Apetoh","year":"2007","unstructured":"Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050\u20131059 (2007).","journal-title":"Nat. Med"},{"key":"11238_CR34","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2015.209","volume":"13","author":"MJ Smyth","year":"2016","unstructured":"Smyth, M. J., Ngiow, S. F., Ribas, A. & Teng, M. W. Combination cancer immunotherapies tailored to the tumour microenvironment. Nat. Rev. Clin. Oncol. 13, 143\u2013158 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"11238_CR35","doi-asserted-by":"publisher","first-page":"370ra180","DOI":"10.1126\/scitranslmed.aag2942","volume":"8","author":"D Mathios","year":"2016","unstructured":"Mathios, D. et al. Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM. Sci. Transl. Med. 8, 370ra180 (2016).","journal-title":"Sci. Transl. Med."},{"key":"11238_CR36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1158\/2326-6066.CIR-17-0356","volume":"6","author":"CE Ariyan","year":"2018","unstructured":"Ariyan, C. E. et al. Robust antitumor responses result from local chemotherapy and CTLA-4 blockade. Cancer Immunol. Res. 6, 189\u2013200 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"11238_CR37","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1158\/2326-6066.CIR-14-0118","volume":"3","author":"S Chen","year":"2015","unstructured":"Chen, S. et al. Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector\/memory CD8 T cells in a poorly immunogenic tumor model. Cancer Immunol. Res. 3, 149\u2013160 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"11238_CR38","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107, 4275\u20134280 (2010).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"11238_CR39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2016.12.005","volume":"45","author":"J Qiao","year":"2017","unstructured":"Qiao, J., Tang, H. & Fu, Y. X. DNA sensing and immune responses in cancer therapy. Curr. Opin. Immunol. 45, 16\u201320 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"11238_CR40","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1038\/ni.2703","volume":"14","author":"TF Gajewski","year":"2013","unstructured":"Gajewski, T. F., Schreiber, H. & Fu, Y. X. Innate and adaptive immune cells in the tumor microenvironment. Nat. Immunol. 14, 1014\u20131022 (2013).","journal-title":"Nat. Immunol."},{"key":"11238_CR41","first-page":"201","volume":"12","author":"J Kleponis","year":"2015","unstructured":"Kleponis, J., Skelton, R. & Zheng, L. Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors. Cancer Biol. Med. 12, 201\u2013208 (2015).","journal-title":"Cancer Biol. Med."},{"key":"11238_CR42","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1126\/science.aaf0683","volume":"355","author":"AO Kamphorst","year":"2017","unstructured":"Kamphorst, A. O. et al. Rescue of exhausted CD8 T cells by PD-1-targeted therapies is CD28-dependent. Science 355, 1423\u20131427 (2017).","journal-title":"Science"},{"key":"11238_CR43","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1158\/2326-6066.CIR-15-0064","volume":"3","author":"LA Emens","year":"2015","unstructured":"Emens, L. A. & Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol. Res. 3, 436\u2013443 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"11238_CR44","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.immuni.2015.11.024","volume":"44","author":"C Pfirschke","year":"2016","unstructured":"Pfirschke, C. et al. Immunogenic chemotherapy sensitizes tumors to checkpoint blockade therapy. Immunity 44, 343\u2013354 (2016).","journal-title":"Immunity"},{"key":"11238_CR45","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","volume":"17","author":"CJ Langer","year":"2016","unstructured":"Langer, C. J. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497\u20131508 (2016).","journal-title":"Lancet Oncol."},{"key":"11238_CR46","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","volume":"378","author":"L Gandhi","year":"2018","unstructured":"Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078\u20132092 (2018).","journal-title":"N. Engl. J. Med."},{"key":"11238_CR47","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/bjc.2017.145","volume":"117","author":"GJ Weiss","year":"2017","unstructured":"Weiss, G. J. et al. A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus). Br. J. Cancer 117, 33\u201340 (2017).","journal-title":"Br. J. Cancer"},{"key":"11238_CR48","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.ccell.2018.03.005","volume":"33","author":"R Zappasodi","year":"2018","unstructured":"Zappasodi, R., Merghoub, T. & Wolchok, J. D. Emerging concepts for immune checkpoint blockade-based combination therapies. Cancer Cell 33, 581\u2013598 (2018).","journal-title":"Cancer Cell"},{"key":"11238_CR49","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med"},{"key":"11238_CR50","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1146\/annurev-med-012017-043208","volume":"69","author":"M Hashimoto","year":"2018","unstructured":"Hashimoto, M. et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 69, 301\u2013318 (2018).","journal-title":"Annu. Rev. Med"},{"key":"11238_CR51","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252\u2013264 (2012).","journal-title":"Nat. Rev. Cancer"},{"key":"11238_CR52","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","volume":"366","author":"SL Topalian","year":"2012","unstructured":"Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443\u20132454 (2012).","journal-title":"N. Engl. J. Med"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11238-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11238-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11238-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T19:26:14Z","timestamp":1671218774000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-11238-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["11238"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-11238-1","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,19]]},"assertion":[{"value":"5 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3251"}}